About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Ins2
insulin II
MGI:96573
77 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Bdkrb2tm1Jfh/Bdkrb2tm1Jfh
Ins2Akita/Ins2+
B6.Cg-Ins2Akita Bdkrb2tm1Jfh
abnormal intestinal epithelium morphology J:108948
abnormal Leydig cell morphology J:108948
abnormal mitochondrial chromosome morphology J:108948
abnormal seminiferous tubule morphology J:108948
abnormal spermatogonia morphology J:108948
alopecia J:108948
decreased bone mineral density J:108948
decreased subcutaneous adipose tissue amount J:108948
kyphosis J:108948
premature death J:108948
Cebpbtm1.1Maka/Cebpbtm1.1Maka
Ins2Akita/Ins2Akita
Tg(Ins2-cre)23Herr/0
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NSlc * CBA/J
abnormal pancreatic beta cell mass J:156725
abnormal pancreatic islet cell apoptosis J:156725
decreased circulating insulin level J:156725
decreased insulin secretion J:156725
increased circulating glucose level J:156725
Dbm1A/J/Dbm1A/J
Ins2Akita/Ins2+
involves: A/J * C57BL/6J * C57BL/6NSlc
increased body weight J:112869
increased circulating glucose level J:112869
increased circulating insulin level J:112869
Dbm3C57BL/6J/?
Ins2Akita/Ins2+
involves: A/J * C57BL/6J * C57BL/6NSlc
abnormal circulating glucose level J:112869
Dbm4C57BL/6J/?
Ins2Akita/Ins2+
involves: A/J * C57BL/6J * C57BL/6NSlc
abnormal circulating glucose level J:112869
Ero1lbGt(P077G11)Wrst/Ero1lb+
Ins2Akita/Ins2+
involves: 129S2/SvPas * C57BL/6NSlc
decreased insulin secretion J:158805
impaired glucose tolerance J:158805
increased circulating glucose level J:158805
small pancreatic islets J:158805
Gasttm1(INS)Ez/Gast+
Ins2Akita/Ins2+
involves: 129S4/SvJae * C57BL/6NSlc
abnormal circulating glucose level J:99270
normal mortality/aging J:99270
H2g7/H2g7
Ins2tm1Jja/Ins2tm1Jja
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD
increased circulating glucose level J:111874
increased susceptibility to autoimmune diabetes J:111874
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1.1Mnt/Ins2tm1.1Mnt
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N
postnatal lethality, complete penetrance J:152798
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2+
involves: 129S2/SvPas * C57BL/6
abnormal pancreatic alpha cell morphology J:106827
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
involves: 129S2/SvPas
abnormal glucose homeostasis J:40377, J:77595
acidosis J:40377
decreased body size J:40377
embryonic growth retardation J:40377
enlarged liver J:40377
enlarged pancreatic islets J:40377
hepatic steatosis J:40377
increased circulating triglyceride level J:40377
increased pancreatic beta cell number J:77595
increased urine glucose level J:40377
postnatal lethality, complete penetrance J:40377
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
involves: 129S2/SvPas * C57BL/6
abnormal pancreatic alpha cell morphology J:106827
abnormal pancreatic islet morphology J:106827
decreased apoptosis J:106827
decreased birth weight J:106827
decreased fetal weight J:106827
enlarged pancreatic islets J:106827
increased pancreatic beta cell mass J:106827
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
Tg(Ins2*Y16A)1Ell/0
NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell
decreased susceptibility to autoimmune diabetes J:98583
increased circulating glucose level J:98583
salivary gland inflammation J:98583
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
Tg(Ins2*Y16A)3Ell/0
NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)3Ell
decreased anti-insulin autoantibody level J:98583
decreased susceptibility to autoimmune diabetes J:98583
salivary gland inflammation J:98583
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Mnt/Ins2tm1Mnt
Tg(Aire-cre)1Mnt/0
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N
abnormal circulating insulin level J:152798
abnormal immune system physiology J:152798
abnormal interferon-gamma secretion J:152798
abnormal pancreatic beta cell physiology J:152798
abnormal T cell physiology J:152798
decreased pancreatic beta cell number J:152798
hyperglycemia J:152798
increased anti-insulin autoantibody level J:152798
increased circulating glucose level J:152798
pancreas inflammation J:152798
Ins1tm1Jja/Ins1tm1Jja
Tg(Ins2*Y16A)1Ell/0
NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)1Ell
increased circulating glucose level J:98583
increased susceptibility to autoimmune diabetes J:98583
Ins1tm1Jja/Ins1tm1Jja
Tg(Ins2*Y16A)3Ell/0
NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)3Ell
autoimmune response J:98583
Ins2Akita/Ins2+
Prf1tm1Sdz/Prf1tm1Sdz
Rag1tm1Mom/Rag1tm1Mom
NOD.Cg-Rag1tm1Mom Ins2Akita Prf1tm1Sdz
abnormal glucose homeostasis J:138005
abnormal pancreatic islet morphology J:138005
absent mature B cells J:138005
absent T cells J:138005
normal homeostasis/metabolism phenotype J:138005
hyperglycemia J:138005
increased erythrocyte cell number J:138005
increased granulocyte number J:138005
increased macrophage cell number J:138005
increased monocyte cell number J:138005
Ins2Akita/Ins2+
Rnf213tm1.1Akoi/Rnf213tm1.1Akoi
involves: C57BL/6N * C57BL/6NSlc
abnormal pancreatic islet morphology J:200802
decreased body weight J:200802
decreased circulating leptin level J:200802
decreased insulin secretion J:200802
decreased pancreatic beta cell number J:200802
normal homeostasis/metabolism phenotype J:200802
impaired glucose tolerance J:200802
increased circulating glucose level J:200802
increased food intake J:200802
Ins2Akita/Ins2Akita
Itga1tm1Gdnr/Itga1tm1Gdnr
C.Cg-Ins2Akita Itga1tm1Gdnr
abnormal glomerular capillary morphology J:198186
abnormal glomerular mesangium morphology J:198186
abnormal kidney interstitium morphology J:198186
albuminuria J:198186
decreased body weight J:198186
expanded mesangial matrix J:198186
glomerulosclerosis J:198186
hyperglycemia J:198186
increased renal glomerular filtration rate J:198186
increased renal glomerulus basement membrane thickness J:198186
mesangiolysis J:198186
premature death J:198186
renal glomerular protein deposits J:198186
Ins2Akita/Ins2Akita
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Ins2Akita Ldlrtm1Her
decreased body weight J:174983
decreased circulating insulin level J:174983
hyperglycemia J:174983
impaired glucose tolerance J:174983
increased circulating cholesterol level J:174983
increased circulating HDL cholesterol level J:174983
increased circulating LDL cholesterol level J:174983
increased circulating triglyceride level J:174983
increased circulating VLDL cholesterol level J:174983
increased susceptibility to atherosclerosis J:174983
premature death J:174983
Ins2Akita/Ins2Akita
Prf1tm1Sdz/Prf1tm1Sdz
Rag1tm1Mom/Rag1tm1Mom
NOD.Cg-Rag1tm1Mom Ins2Akita Prf1tm1Sdz
postnatal lethality, complete penetrance J:138005
Ins2Akita/Ins2Akita
Rpl13atm1.1Jesc/Rpl13atm1.1Jesc
FVB.Cg-Rpl13atm1.1Jesc Ins2Akita
abnormal circulating glucose level J:237822
Ins2tm1Jja/Ins2tm1Jja
Tg(Ins2*Y16A)3Ell/0
NOD.Cg-Ins2tm1Jja Tg(Ins2*Y16A)3Ell
autoimmune response J:98583
increased anti-insulin autoantibody level J:98583
Tg(Ins2*Y16A)1Ell/0
NOD-Tg(Ins2*Y16A)1Ell
increased susceptibility to autoimmune diabetes J:98583
Tg(Ins2*Y16A)3Ell/0
NOD-Tg(Ins2*Y16A)3Ell
increased susceptibility to autoimmune diabetes J:98583

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
05/15/2018
MGI 6.12
The Jackson Laboratory